(ISRG) Intuitive Surgical - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US46120E6023
da Vinci, Ion, Stapling, Energy, Support
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 30.4% |
| Value at Risk 5%th | 44.7% |
| Relative Tail Risk | -10.47% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.05 |
| Alpha | -15.90 |
| CAGR/Max DD | 0.92 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.435 |
| Beta | 1.215 |
| Beta Downside | 1.241 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.63% |
| Mean DD | 8.52% |
| Median DD | 5.86% |
Description: ISRG Intuitive Surgical December 01, 2025
Intuitive Surgical, Inc. (NASDAQ: ISRG) designs, manufactures, and markets robotic-assisted platforms that enable minimally invasive procedures for hospitals worldwide, with its flagship da Vinci Surgical System and the newer Ion endoluminal system for lung biopsies.
Beyond the hardware, the company supplies a full suite of stapling, energy, and core instruments, offers structured learning pathways for surgeons, and maintains a comprehensive service network that includes installation, 24/7 technical support, proactive system health monitoring, and data-driven analytics to improve operating room efficiency.
In FY 2023, ISRG generated roughly $5.6 billion in revenue, growing ~28% year-over-year, and posted an operating margin near 30%; the firm commands roughly 70% of the U.S. robotic-surgery market, a share bolstered by rising hospital capital spending and an aging population that drives demand for minimally invasive, outpatient procedures. For a deeper quantitative assessment, you may find ValueRay’s platform useful for benchmarking ISRG against peers.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (2.75b TTM) > 0 and > 6% of Revenue (6% = 576.7m TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA 8.43pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 69.93% (prev 70.41%; Δ -0.47pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.15 (>3.0%) and CFO 2.96b > Net Income 2.75b (YES >=105%, WARN >=100%) |
| Net Debt (-2.81b) to EBITDA (3.58b) ratio: -0.78 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.73 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (361.8m) change vs 12m ago -0.25% (target <= -2.0% for YES) |
| Gross Margin 66.41% (prev 66.98%; Δ -0.57pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 51.82% (prev 44.34%; Δ 7.49pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 33.19 (EBITDA TTM 3.58b / Interest Expense TTM 90.4m) >= 6 (WARN >= 3) |
Altman Z'' 7.38
| (A) 0.35 = (Total Current Assets 8.53b - Total Current Liabilities 1.80b) / Total Assets 19.35b |
| (B) 0.33 = Retained Earnings (Balance) 6.42b / Total Assets 19.35b |
| (C) 0.16 = EBIT TTM 3.00b / Avg Total Assets 18.55b |
| (D) 2.79 = Book Value of Equity 6.45b / Total Liabilities 2.31b |
| Total Rating: 7.38 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 81.87
| 1. Piotroski 7.0pt |
| 2. FCF Yield 1.13% |
| 3. FCF Margin 23.63% |
| 4. Debt/Equity 0.01 |
| 5. Debt/Ebitda -0.78 |
| 6. ROIC - WACC (= 4.09)% |
| 7. RoE 16.08% |
| 8. Rev. Trend 97.47% |
| 9. EPS Trend 92.84% |
What is the price of ISRG shares?
As of December 13, 2025, the stock is trading at USD 542.32 with a total of 2,116,253 shares traded.
Over the past week, the price has changed by -5.74%, over one month by -5.26%, over three months by +20.60% and over the past year by -0.44%.
Over the past week, the price has changed by -5.74%, over one month by -5.26%, over three months by +20.60% and over the past year by -0.44%.
Is ISRG a buy, sell or hold?
Intuitive Surgical has received a consensus analysts rating of 4.03.
Therefore, it is recommended to buy ISRG.
- Strong Buy: 14
- Buy: 8
- Hold: 10
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the ISRG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 596.4 | 10% |
| Analysts Target Price | 596.4 | 10% |
| ValueRay Target Price | 630.9 | 16.3% |
ISRG Fundamental Data Overview December 09, 2025
Market Cap USD = 206.25b (206.25b USD * 1.0 USD.USD)
P/E Trailing = 76.305
P/E Forward = 47.8469
P/S = 21.4571
P/B = 12.0472
P/EG = 2.7875
Beta = 1.686
Revenue TTM = 9.61b USD
EBIT TTM = 3.00b USD
EBITDA TTM = 3.58b USD
Long Term Debt = unknown (none)
Short Term Debt = 33.5m USD (from shortTermDebt, last fiscal year)
Debt = 146.0m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -2.81b USD (from netDebt column, last quarter)
Enterprise Value = 201.48b USD (206.25b + Debt 146.0m - CCE 4.91b)
Interest Coverage Ratio = 33.19 (Ebit TTM 3.00b / Interest Expense TTM 90.4m)
FCF Yield = 1.13% (FCF TTM 2.27b / Enterprise Value 201.48b)
FCF Margin = 23.63% (FCF TTM 2.27b / Revenue TTM 9.61b)
Net Margin = 28.58% (Net Income TTM 2.75b / Revenue TTM 9.61b)
Gross Margin = 66.41% ((Revenue TTM 9.61b - Cost of Revenue TTM 3.23b) / Revenue TTM)
Gross Margin QoQ = 66.36% (prev 66.44%)
Tobins Q-Ratio = 10.41 (Enterprise Value 201.48b / Total Assets 19.35b)
Interest Expense / Debt = 61.92% (Interest Expense 90.4m / Debt 146.0m)
Taxrate = 17.07% (146.0m / 855.2m)
NOPAT = 2.49b (EBIT 3.00b * (1 - 17.07%))
Current Ratio = 4.73 (Total Current Assets 8.53b / Total Current Liabilities 1.80b)
Debt / Equity = 0.01 (Debt 146.0m / totalStockholderEquity, last quarter 16.93b)
Debt / EBITDA = -0.78 (Net Debt -2.81b / EBITDA 3.58b)
Debt / FCF = -1.24 (Net Debt -2.81b / FCF TTM 2.27b)
Total Stockholder Equity = 17.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.19% (Net Income 2.75b / Total Assets 19.35b)
RoE = 16.08% (Net Income TTM 2.75b / Total Stockholder Equity 17.08b)
RoCE = 17.10% (EBIT 3.00b / Capital Employed (Total Assets 19.35b - Current Liab 1.80b))
RoIC = 14.57% (NOPAT 2.49b / Invested Capital 17.08b)
WACC = 10.48% (E(206.25b)/V(206.39b) * Re(10.49%) + (debt cost/tax rate unavailable))
Discount Rate = 10.49% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.50%
[DCF Debug] Terminal Value 67.19% ; FCFE base≈1.60b ; Y1≈1.40b ; Y5≈1.13b
Fair Price DCF = 39.77 (DCF Value 14.10b / Shares Outstanding 354.5m; 5y FCF grow -15.34% → 3.0% )
EPS Correlation: 92.84 | EPS CAGR: 17.76% | SUE: 3.30 | # QB: 2
Revenue Correlation: 97.47 | Revenue CAGR: 13.64% | SUE: 1.55 | # QB: 5
EPS next Quarter (2026-03-31): EPS=2.12 | Chg30d=+0.066 | Revisions Net=+13 | Analysts=22
EPS next Year (2026-12-31): EPS=9.73 | Chg30d=+0.046 | Revisions Net=+1 | Growth EPS=+12.7% | Growth Revenue=+15.1%
P/E Trailing = 76.305
P/E Forward = 47.8469
P/S = 21.4571
P/B = 12.0472
P/EG = 2.7875
Beta = 1.686
Revenue TTM = 9.61b USD
EBIT TTM = 3.00b USD
EBITDA TTM = 3.58b USD
Long Term Debt = unknown (none)
Short Term Debt = 33.5m USD (from shortTermDebt, last fiscal year)
Debt = 146.0m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -2.81b USD (from netDebt column, last quarter)
Enterprise Value = 201.48b USD (206.25b + Debt 146.0m - CCE 4.91b)
Interest Coverage Ratio = 33.19 (Ebit TTM 3.00b / Interest Expense TTM 90.4m)
FCF Yield = 1.13% (FCF TTM 2.27b / Enterprise Value 201.48b)
FCF Margin = 23.63% (FCF TTM 2.27b / Revenue TTM 9.61b)
Net Margin = 28.58% (Net Income TTM 2.75b / Revenue TTM 9.61b)
Gross Margin = 66.41% ((Revenue TTM 9.61b - Cost of Revenue TTM 3.23b) / Revenue TTM)
Gross Margin QoQ = 66.36% (prev 66.44%)
Tobins Q-Ratio = 10.41 (Enterprise Value 201.48b / Total Assets 19.35b)
Interest Expense / Debt = 61.92% (Interest Expense 90.4m / Debt 146.0m)
Taxrate = 17.07% (146.0m / 855.2m)
NOPAT = 2.49b (EBIT 3.00b * (1 - 17.07%))
Current Ratio = 4.73 (Total Current Assets 8.53b / Total Current Liabilities 1.80b)
Debt / Equity = 0.01 (Debt 146.0m / totalStockholderEquity, last quarter 16.93b)
Debt / EBITDA = -0.78 (Net Debt -2.81b / EBITDA 3.58b)
Debt / FCF = -1.24 (Net Debt -2.81b / FCF TTM 2.27b)
Total Stockholder Equity = 17.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.19% (Net Income 2.75b / Total Assets 19.35b)
RoE = 16.08% (Net Income TTM 2.75b / Total Stockholder Equity 17.08b)
RoCE = 17.10% (EBIT 3.00b / Capital Employed (Total Assets 19.35b - Current Liab 1.80b))
RoIC = 14.57% (NOPAT 2.49b / Invested Capital 17.08b)
WACC = 10.48% (E(206.25b)/V(206.39b) * Re(10.49%) + (debt cost/tax rate unavailable))
Discount Rate = 10.49% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.50%
[DCF Debug] Terminal Value 67.19% ; FCFE base≈1.60b ; Y1≈1.40b ; Y5≈1.13b
Fair Price DCF = 39.77 (DCF Value 14.10b / Shares Outstanding 354.5m; 5y FCF grow -15.34% → 3.0% )
EPS Correlation: 92.84 | EPS CAGR: 17.76% | SUE: 3.30 | # QB: 2
Revenue Correlation: 97.47 | Revenue CAGR: 13.64% | SUE: 1.55 | # QB: 5
EPS next Quarter (2026-03-31): EPS=2.12 | Chg30d=+0.066 | Revisions Net=+13 | Analysts=22
EPS next Year (2026-12-31): EPS=9.73 | Chg30d=+0.046 | Revisions Net=+1 | Growth EPS=+12.7% | Growth Revenue=+15.1%
Additional Sources for ISRG Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle